Abbonarsi

Next-generation sequencing improves the detection of malignant biliary strictures and changes management - 14/06/25

Doi : 10.1016/j.gie.2024.12.024 
Olgert Bardhi, MD, MS 1, Alex Jones, MD 1, Daniel Ellis, MD 2, Thomas Tielleman, MD 2, Anna Tavakkoli, MD 2, Dutch Vanderveldt, MD 2, Markus Goldschmiedt, MD 2, Aatur Singhi, MD 3, Nisa Kubiliun, MD 2, Tarek Sawas, MD, MPH 2,
1 Department of Medicine, University of Texas Southwestern, Dallas, Texas, USA 
2 Division of Digestive and Liver Diseases, University of Texas Southwestern, Dallas, Texas, USA 
3 Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA 

Corresponding author: Tarek Sawas, MD, MPH, Division of Digestive and Liver Diseases, University of Texas Southwestern, 1801 Inwood Rd, Suite 6-102, Dallas, TX 75235.Division of Digestive and Liver DiseasesUniversity of Texas Southwestern1801 Inwood RdSuite 6-102DallasTX75235

Abstract

Background and Aims

Malignant biliary strictures (MBSs) pose diagnostic and therapeutic challenges due to the frequent indeterminate results after initial sampling. A next-generation sequencing (NGS) panel (BiliSeq) offers promise in MBS detection, but real-world performance remains uncertain. This study aimed to assess standard sampling techniques alone and with BiliSeq for malignancy detection in biliary strictures and to evaluate management changes based on NGS.

Methods

This retrospective cohort study included 77 patients with biliary strictures undergoing BiliSeq during ERCP. Sensitivity, specificity, positive predictive values, and negative predictive values were calculated, and sensitivity was compared between tests by using the McNemar test. Clinical impact was defined by identifying MBS patients with negative cytology/pathology correctly identified by BiliSeq.

Results

Among 77 patients (28 malignant, 49 benign) who underwent BiliSeq testing during ERCP, primary sclerosing cholangitis was present in 24 patients (31.2%). A mass was detected in 35.7% of MBS cases versus 6.1% of benign cases (P = .001). BiliSeq sensitivity for malignancy was 75% (95% CI, 55.1%-89.3%), surpassing the combination of cytology and biopsy (42.9%; 95% CI, 24.5%-62.8%; P = .03). Combining BiliSeq with cytology/biopsy improved sensitivity from 42.9% to 85.7% (P < .001). Among MBS patients with negative cytology/biopsy findings (n = 16), BiliSeq altered management in 75%.

Conclusions

NGS and pathologic evaluation enhanced MBS detection sensitivity, leading to management changes in 75% of cases when pathology test results were negative.

Il testo completo di questo articolo è disponibile in PDF.

Graphical abstract




Il testo completo di questo articolo è disponibile in PDF.

Abbreviations : BC, CCA, CI, FISH, MBS, NGS, NPV, PPV, PSC, ROC, SOC, TPB


Mappa


 DIVERSITY, EQUITY, AND INCLUSION: We worked to ensure gender balance in the recruitment of human subjects. One or more of the authors of this paper self-identifies as an under-represented gender minority in science. The author list of this paper includes contributors from the location where the research was conducted who participated in the data collection, design, analysis, and/or interpretation of the work.


© 2025  American Society for Gastrointestinal Endoscopy. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 102 - N° 1

P. 56 - luglio 2025 Ritorno al numero
Articolo precedente Articolo precedente
  • Comparative efficacy and safety of 3 endoscopic techniques for the treatment of large common bile duct stones (≥15 mm): long-term follow-up
  • Jia Wang, Lichao Cao, Yuchen Cong, Yining Huang, Lei Wang, Wenjing Wang, Kuijin Xue, Qingdong Mao, Peng Qi, Hui Ju, Baoguo He, Bin Cao
| Articolo seguente Articolo seguente
  • Current-generation sequencing: Has the next generation of malignant biliary stricture identification arrived?
  • Omeed Alipour

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.